Patient P-02542

Synthetic patientMETA-24 · Day 177 · 25–34 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 12 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −22% vs expected — Dietary Support Protocol NP-02
Day 64 Tolerance state changed — Unstable → Improving
Day 93 ME-01 recommended — Monitoring Escalation ME-01
Day 94 Patient accepted — Started ME-01 in the companion
Day 97 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 12.

Primary contributors, last 14 days

GI instability+21
Nutritional resilience-11
Inflammatory activity+7
Treatment adherence-2
Toxicity-2

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −22%
Monitoring Escalation ME-01Day 93
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

0 min

worsening · -3.8 vs previous 14 d

Sleep duration

Wearable

5.6 h

stable · +0.1 vs previous 14 d

Energy level

Daily log

2.3/10

worsening · -0.5 vs previous 14 d

Steps

Wearable

300

worsening · -244 vs previous 14 d

GI burden

Companion

68.8/100

worsening · +7.6 vs previous 14 d

Adherence

Companion

41.8 %

stable · +0.0 vs previous 14 d

Sleep quality

Wearable

5.9/100

improving · +1.2 vs previous 14 d

Glucose, CGM daily mean

CGM

150 mg/dL

stable · +2.9 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 21 from the failing basin, 73 from restoration.

Would help

GI-04 GI Support Protocol
75% improved among 65 similar · onset 8 d · confidence 97%
SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 75%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 75%
More protein
GI -4.7 next day on high-intake days · n 23

Would not help

Keep ultra-processed low
GI +5.4 next day on high-intake days · n 21
Keep fat low
GI +4.2 next day on high-intake days · n 15
Keep simple carbs low
GI +2.7 next day on high-intake days · n 16

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Ultra-processed food
+5.4detractor · 95%
Protein
-4.7supporter · 95%
Dietary fat load
+4.2detractor · 95%
Simple carbohydrates
+2.7detractor · 76%
Histamine load
-1.2no signal · 26%
Insoluble fibre
+1no signal · 26%
Caffeine
-0.7no signal · 15%
Alcohol
-0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 62
- WearableHRV 16 ms, trending down
Autonomic recovery ↓65
- WearableResting HR 86 bpm
- Wearable300 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 69 and rising
- WearableSleep 5.6 h, below personal baseline
Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 51

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.8 · butyrate capacity 46/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 5.6 h
Steps: 822
Resting HR: 85 bpm

Daily log: GI score 69, nutritional resilience 31, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02048	18%	S02	—	—	77
P-02115	20%	S14	GI-04	improved	75
P-02575	21%	S14	ME-01	improved	73
P-02550	19%	S01	—	—	70
P-02192	18%	S05	—	—	69
P-02659	22%	S09	—	—	69
P-02293	18%	S15	HY-01	no change	68
P-02591	30%	S13	—	—	68
P-02090	18%	S04	—	—	68
P-02265	29%	S07	GI-04	no change	67
P-02530	30%	S07	—	—	67
P-02194	18%	S03	—	—	67